ML-9 Free Base
Based on 6 publication(s) in Google Scholar
ML-9 (Free Base) is a selective and potent inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity. ML-9 (Free Base) inhibits inhibits MLCK, PKA and PKC activity with Ki values of 4, 32 and 54 μM, respectively. ML-9 (Free Base) induces autophagy by stimulating autophagosome formation and inhibiting their degradation.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 110448-31-2
- Formule: C15H17ClN2O2S
- Masse moléculaire:324.83
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) ML-9 Free Base
More
Activité biologique
ML9 (Free Base) (0-100 μM; 0-24 hours) has no reduction in cardiomyocyte viability, 50-100 μM significantly induces cell death[2]. ML9 (Free Base) (50 μM; 1-4 hours) significantly increases cleaved caspase-3 levels, decreased STIM1 protein levels by about 42%[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Neonatal rat ventricular myocytes (NRVM) cells
-
Concentration:0, 10, 50 and 100 μM
-
Incubation Time:0, 1, 4, 8 and 24 hours
-
Result:Decreased cell viability at 50–100 μM concentration.
-
Cell Line:Neonatal rat ventricular myocytes (NRVM) cells
-
Concentration:50 μM
-
Incubation Time:0, 1, 4, 8 hours
-
Result:Induced cardiomyocyte death through necrosis and apoptosis.
Chemical Information
-
CAS No. 110448-31-2
-
Masse moléculaire 324.83
-
Formule C15H17ClN2O2S
-
SMILES
O=S(N1CCNCCC1)(C2=C3C=CC=C(C3=CC=C2)Cl)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Eur J Pharmacol
Novel mechanisms of metformin-induced vasorelaxation of mesenteric arterioles via endothelium-dependent hyperpolarization to treat murine colitis. [Abstract]2025 Sep 15:1003:177900. PMID: 40617384 -
Cell Calcium
Drug repurposing DMSO from an old solvent to a new candidate for the treatment of colitis and sepsis in male mice. [Abstract]2026 May 23:136:103155. PMID: 42235215 -
Cell Calcium
High-throughput assessment identifying major platelet Ca2+ entry pathways via tyrosine kinase-linked and G protein-coupled receptors. [Abstract]2023 Jun:112:102738. PMID: 37060673 -
Life Sci Alliance
JAK inhibition with tofacitinib rapidly increases contractile force in human skeletal muscle. [Abstract]2024 Aug 9;7(11):e202402885. PMID: 39122555 -
Heliyon
N,N,N',N'-Tetrakis(2-pyridylmethyl)ethylenediamine induces endothelium-dependent hyperpolarization-mediated vasorelaxation via store-operated calcium entry mechanism in healthy and intestinal inflammatory mice. [Abstract]2024 Jul 6;10(14):e33994. PMID: 39108891 -
Pureté et documentation
Références
[1]. Ito S, et al. ML-9, a myosin light chain kinase inhibitor, reduces intracellular Ca2+ concentration in guinea pig trachealis.Eur J Pharmacol. 2004 Feb 23;486(3):325-33. [Content Brief]
[2]. Shaikh S, et al. The STIM1 inhibitor ML9 disrupts basal autophagy in cardiomyocytes by decreasing lysosome content.Toxicol In Vitro. 2018 Apr;48:121-127. [Content Brief]
[3]. Kondratskyi A1, et al.Identification of ML-9 as a lysosomotropic agent targeting autophagy and cell death.Cell Death Dis. 2014 Apr 24;5:e1193. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
ML-9 Free Base Related Classifications
HY-100932A Related Classifications
Powered by Bioz